Jaguar Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. (JAGX) on May 10, 2023. The Company is incorporated in Delaware and its common stock trades on The NASDAQ Capital Market. The report addresses a specific regulatory event regarding the Company's continued listing status on the exchange.
Key Financial Metrics
This filing does not contain comprehensive financial statements, revenue, profit, or cash flow data. The only financial metric disclosed is that the Company currently holds stockholders' equity of at least $5 million, which is a criterion for potential listing extensions.
Material Changes and Listing Status
On May 10, 2023, the Company received notice from the Nasdaq Listing Qualifications Staff that its common stock had closed below the minimum $1.00 per share bid price requirement for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). Consequently, the Company has been granted a 180-calendar-day grace period to regain compliance, expiring on November 6, 2023.
- Compliance Requirement: The Company must evidence a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days during the grace period.
- Extension Criteria: To qualify for an additional extension beyond November 6, 2023, the Company must meet the market value of publicly held shares requirement and all other initial listing standards, excluding the minimum bid price.
- Current Status: The Company meets the stockholders' equity threshold ($5 million) required to be considered for an extension if measured today.
Outlook, Risks, and Management Commentary
Management states it is diligently working to regain compliance with the minimum bid price requirement. However, the filing explicitly states there can be no assurance that the Company will be able to regain compliance or that Nasdaq will grant a further extension. If the Company fails to meet the requirements by the deadline, its common stock will be subject to delisting from Nasdaq.
The report includes standard forward-looking statement disclaimers, noting that actual results may differ materially from expectations due to various risk factors detailed in the Company's 2022 Form 10-K.
Investor Verification Checklist
- Monitor the daily closing bid price of JAGX to track progress toward the $1.00 threshold.
- Verify the Company's market value of publicly held shares to assess eligibility for a potential second grace period.
- Review the Company's 2022 Form 10-K for detailed risk factors and financial condition.
- Watch for subsequent 8-K filings regarding the Company's compliance status or any reverse stock split proposals.